Device Trial Radar · NCT05077657
Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System
Last checked: Nov 20, 2026Latest source record: Feb 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Nov 29, 2021
Primary completion
Dec 19, 2023
Study completion Dec 19, 2023
Sponsor
- Lead sponsor
- Saranas, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Proxima CRO; Cardiovascular Research Foundation, New York
- First posted
- Oct 14, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to establish the safety of complex high-risk Percutaneous Coronary Intervention (PCI) using Mechanical Circulatory Support (MCS) and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).
Conditions
- Coronary Artery Disease
Interventions
Early Bird® Bleed Monitoring SystemDevice
The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.
Impella®Device
Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of access site related BARC type III or V bleedingTime frame: Within 24 hours
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
St. Joseph Hospital / Arizona Heart
Phoenix, Arizona
Tucson Medical Center / PIMA Heart
Tucson, Arizona
Methodist Hospitals
Gary, Indiana
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.